144. レノックス・ガストー症候群 Lennox-Gastaut syndrome Clinical trials / Disease details
臨床試験数 : 111 / 薬物数 : 72 - (DrugBank : 14) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 61
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05626634 (ClinicalTrials.gov) | November 8, 2022 | 15/11/2022 | Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy | A Phase 2, Multicenter, Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy Who Completed Study LP352-201 and Are Candidates for Continuous Treatment for Up to 52 Weeks | Developmental and Epileptic Encephalopathy;Dravet Syndrome;Lennox-Gastaut Syndrome | Drug: LP352 | Longboard Pharmaceuticals | NULL | Recruiting | 12 Years | 65 Years | All | 50 | Phase 2 | United States |
2 | NCT05364021 (ClinicalTrials.gov) | March 3, 2022 | 22/3/2022 | Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies | Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, PK, PD, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies | Developmental and Epileptic Encephalopathy;Dravet Syndrome;Lennox Gastaut Syndrome | Drug: LP352;Drug: Placebo | Longboard Pharmaceuticals | NULL | Recruiting | 12 Years | 65 Years | All | 50 | Phase 1/Phase 2 | United States |